[Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
We compared the number of new gadolinium-enhancing (Gd+) and T2-weighted (T2W) lesions on 6-monthly MRI scans before and after initiating weekly intramuscular injections of interferon beta-1a (Avonex) 30 mcg. The mean number of new focal Gd+ lesions detected during the 6 monthly on-treatment scanning sessions was 58 per cent less per MRI scan and 62.5 per cent less per patient than during the 6 monthly pre-treatment scanning sessions (p = 0.016, Wilcoxon signed rank test). The results are similar for new focal Gd+ and T2W lesions. The reduction in disease activity detected by monthly Gd+ enhanced MRI scans after initiating weekly intramuscular interferon beta-1a 30 mcg is consistent with benefits observed with thrice weekly subcutaneous interferon beta-1a 10 and 30 mcg and alternate day subcutaneous interferon beta-1b 8.0 MIU.
Waubant
E
E
UCSF/Mt Zion Multiple Sclerosis Center, San Francisco, CA 94115, USA.
Sloan
R
R
Andersson
P B
PB
Goodkin
D
D
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001921:Brain / Q000473:pathology*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology*; D010865:Pilot Projects; D012008:Recurrence; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a
Effet d'injections intramusculaires hebdomadaires d'interféron beta-1a sur la formation de lésions IRM chez des patients présentant une sclérose en plaques rémittente.